ArticleBMC psychiatry2025
A study on the effect of COVID-19 infection on the serum concentration of antipsychotic drugs.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThe purpose of this study was to investigate the effect of COVID-19 infection on antipsychotic drug concentrations.
methodsThe drug concentration data of schizophrenia patients taking antipsychotic drugs before and after infection with the novel coronavirus were collected from medical records. At the same time, blood and serological test results before and after COVID-19 infection were collected. A total of 139 valid data were collected and analysed statistically.
resultsAfter COVID-19 infection, the serum concentrations of olanzapine, quetiapine, clozapine and risperidone were significantly increased, and the C/D ratio of each drug was significantly increased. After COVID-19 infection, the CRP level, liver function index, kidney function index, blood glucose, blood lipid, electrolyte, myocardial enzyme spectrum, routine blood test results and other indicators changed to varying degrees. An increasing olanzapine concentration was positively correlated with increasing HCY, GLO, SA and MCV. The increasing amplitude of the quetiapine concentration was negatively correlated with the increasing amplitudes of NEFAs and Ca and positively correlated with the increasing amplitude of MON%. An increase in the clozapine concentration was positively correlated with an increase in the CRP level and negatively correlated with an increase in the WBC and NEU%. An increase in the risperidone concentration was positively correlated with increases in the ADA, GGT and RBC levels and negatively correlated with increases in the TBIL, DBIL and BUN levels.
conclusionsCOVID-19 infection resulted in a significant increase in the concentration of antipsychotic drugs and a significant decrease in the metabolic rate of antipsychotic drugs. This may be related to CRP, HCY, ADA, TBIL, DBIL, GGT, GLO, SA, BUN, NEFA, Ca, WBC, NEU#, RBC, and MON%. The monitoring of antipsychotic drug concentrations should be strengthened for patients with COVID-19 infection or other types of inflammation to avoid the occurrence of adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.